Peregrion: obtain human efficacy data in early clinical development

The development time before a new drug is available to patients can extend to well over a decade, with costs running into billions of euros. Peregrion is the latest TNO spin-off company and the result of 10 years of pioneering research. It uses game-changing microtracer AMS technology to obtain human efficacy data in early clinical development, accelerating and de-risking drug development to benefit the industry and human health.